FINWIRES · TerminalLIVE
FINWIRES

$ATR

8 stories mentioning ATRUpdated 5d ago

Every FINWIRES story that references ATR, newest first.

Insider Trading

Aptargroup Insider Sold Shares Worth $1,339,588, According to a Recent SEC Filing

Stephan B. Tanda, Director, President and Chief Executive Officer, on August 03, 2026, sold 9,838 shares in Aptargroup (ATR) for $1,339,588. Following the Form 4 filing with the SEC, Tanda has control over a total of 241,879 common shares of the company, with 238,729 shares held directly and 3,150 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/896622/000089662226000172/xslF345X05/form4.xmlPrice: $136.34, Change: $-0.44, Percent Change: -0.32%

$ATR
Insider Trading

AptarGroup Insider Sold Shares Worth $1,195,290, According to a Recent SEC Filing

Hedi Tlili, Segment President, on August 03, 2026, sold 8,854 shares in AptarGroup (ATR) for $1,195,290. Following the Form 4 filing with the SEC, Tlili has control over a total of 15,379 common shares of the company, with 15,379 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/896622/000089662226000170/xslF345X05/form4.xml

$ATR
Wire

Packaging, Forest Products Face Lackluster Demand, Weak Volumes, BofA Says

Packaging and forest products companies face lackluster demand and weak volumes outside beverage cans and selected specialty markets, BofA Securities analysts said in a Tuesday note.Analysts said that while inflation headwinds are expected to fade in the second half of the year, assuming a renewed ceasefire in the Middle East, foreign exchange could become an earnings risk.BofA said that beverage cans remain its preferred subsector, driven by stronger demand, improving aluminum economics, innovation, and the World Cup.Analysts said they are cautious on glass and paper, where volume weakness and potential operating-rate pressures could weigh on outlooks.BofA upgraded AptarGroup's (ATR) rating to buy from neutral, and raised its price objective to $173 from $148.It downgraded O-I Glass (OI) to underperform from buy, Greif (GEF) to underperform from neutral, and International Paper (IP) and Sylvamo (SLVM) to neutral from buy.BofA also resumed coverage of Graphic Packaging (GPK) with a neutral rating and a $12 price objective.Analysts increased the price objective on Ardagh Metal Packaging (AMBP) to $4.70 from $4; Amcor (AMCR) to $51 from $48; Avery Dennison (AVY) to $210 from $202; Ball (BALL) to $73 from $70; Crown (CCK) to $145 from $129; Karat Packaging (KRT) to $34 from $23; Silgan (SLGN) to $58 from $53; and Sonoco Products (SON) to $69 from $65.They also raised the price objective on Boise Cascade (BCC) to $81 from $80; Louisiana-Pacific (LPX) to $101 from $85; Packaging Corporation of America (PKG) to $263 from $242; and Greif to $70 from $68.BofA lowered its price objective on O-I Glass to $11 from $13, International Paper to $41 from $44, and Sylvamo to $45 from $58.Price: $128.79, Change: $+3.90, Percent Change: +3.12%

$AMBP$AMCR$ATR$AVY$BALL$BCC$CCK$GEF$IP$KRT$LPX$OI$PKG$SLGN$SLVM$SON
Research

BofA Upgrades AptarGroup to Buy From Neutral, Price Target is $173

AptarGroup (ATR) has an average rating of overweight and mean price target of $164, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$ATR
Insider Trading

Aptargroup Insider Sold Shares Worth $577,895, According to a Recent SEC Filing

Marc Prieur, Segment President, on June 09, 2026, sold 5,000 shares in Aptargroup (ATR) for $577,895. Following the Form 4 filing with the SEC, Prieur has control over a total of 19,323 common shares of the company, with 19,323 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/896622/000089662226000139/xslF345X05/form4.xml

$ATR
Insider Trading

Aptargroup Insider Sold Shares Worth $487,765, According to a Recent SEC Filing

Xiangwei Gong, President, Asia, on May 26, 2026, sold 4,200 shares in Aptargroup (ATR) for $487,765. Following the Form 4 filing with the SEC, Gong has control over a total of 11,416 common shares of the company, with 10,774 shares held directly and 642 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/896622/000089662226000132/xslF345X05/form4.xmlPrice: $115.38, Change: $-1.00, Percent Change: -0.86%

$ATR
Research

Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of Aptargroup, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target at $149, 26.8x our 2026 EPS estimate, a premium to its three-year average forward P/E of 26.5x. We trim our 2026 EPS view by $0.12 to $5.56 and decrease our 2027 EPS by $0.15 to $6.40. The injectables division continues to validate our thesis, with 20% Y/Y growth in Q1 as management actively works to increase capacity so the division can expand further. We note that emergency medicine faces a $65M headwind in 1H 2026 as it destocks from prior inventory, which led to flat Q1 core sales and weaker gross margins. Management is confident its pharma growth will expand beyond GLP-1 to both systemic nasal drug delivery and pulmonary biologics. Margin weakness and an unfavorable mix in the Beauty segment are temporary, with normal margins returning in 2H 2026 in our view. We continue to believe ATR is poised to capture significant growth in the biologics markets. ATR could face higher raw material costs as supply chains become stretched due to uncertainty in the Middle East.

$ATR
Research

Research Alert: Aptargroup Q1: Strong Injectables Growth Continues As Margins Decline Y/y

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ATR delivered mixed Q1 2026 results with revenue growth of 11% to $983M (+$27M vs. consensus) but flat core sales, while adjusted EPS declined 8% to $1.19 (+$0.04 vs. consensus). EBITDA margins compressed 150 bps to 19.2%, marking the second consecutive quarter of margin decline due to emergency medicine destocking, unfavorable product mix, and operational challenges. The quarter's results underscore growing operational challenges that are now overshadowing ATR's defensive growth characteristics and end-market positioning. Q2 2026 EPS guidance of $1.32-$1.40 suggests sequential improvement and management expects emergency medicine destocking to moderate. ATR announced Gael Touya as next CEO effective September 1, 2026, and returned $131M to shareholders with 1.4x leverage. Two consecutive quarters of margin compression and flat core sales represent notable deterioration from previously consistent profitability improvement.

$ATR

Track with the FINWIRES app suite